News By Tag
News By Place
Brachytherapy Market Recovery to Reach US$ 2.4 Billion
Brachytherapy market trend is toward a growth driven by new technologies (electronic brachytherapy, microspheres), new indications for LDR (lung, liver) and new markets (Asia, South America).
Brachytherapy has been available commercially since the 1970’s, and while one market segment, the Low-Dose Rate (LDR) brachytherapy seeds market, is under pressure in a few regions, globally a revitalization of the brachytherapy industry is observed for the short term. The trend is toward a growth driven by new technologies (electronic brachytherapy, microspheres)
The global market for brachytherapy reached US$ 680 million in 2013, of which the High-Dose Rate (HDR) and LDR segments accounted for 70%. Microspheres and electronic brachytherapy commanded the remaining 30%. The brachytherapy market is expected to reach over US$ 2.4 billion in 2030, growing by 8% annually, mainly driven by the microspheres market as well as electronic brachytherapy, which is gaining significant interest worldwide as a user-friendly technology. Electronic brachytherapy may also take some shares from the HDR brachytherapy market, as an alternative therapy for some specific indications. Moreover, despite the stagnation of the established markets, the LDR brachytherapy seeds market will grow considerably in substantial new markets such as China and India because of its low cost compared to pharmacological alternatives and its association with a high therapeutic success rate.
This 320-page report is the first comprehensive evaluation of the brachytherapy industry associated with a directory, written by experts, and providing detailed information about products and companies active in this market. It includes a complete description of the radionuclides and devices used in brachytherapy, and contains a detailed profile of 58 companies and institutions active in this field around the world.
More information and table of contents is available at: http://medraysintell.com/
Medical Radiation Strategic Intelligence Experts
Bringing value to Businesses and Investors!
MEDraysintell was created in 2013 by Paul-Emmanuel Goethals (CSIntell) and Richard Zimmermann (Chrysalium Consulting). It combines over 40 years of experience in radiotherapy, particle therapy and nuclear medicine. We aim to form an international team of experts in the field of Medical Radiation industry to provide Strategic Intelligence in nuclear medicine, radiotherapy, proton therapy and brachytherapy to help our clients better understand the markets, competitive environment as well as the potential of merger and acquisitions (M&A) and technology development.
MEDraysintell aims to support in their decisional process manufacturers of radiopharmaceuticals or therapeutic radioisotopes, suppliers of equipment and software as well as investors interested by this industry.
Paul-Emmanuel Goethals and Richard Zimmermann
+32 491 080 968 and +33 6 82 80 06 00